Conklin Michael sold $86K of RYAN

Conklin Michael (EVP & CHRO) sold 2,043 shares of RYAN SPECIALTY HOLDINGS, INC. (RYAN) at $42.26 on 2026-08-13.

Original reporting
SEC EDGAR · Conklin Michael
Published Aug 14, 2026, 9:24 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 14, 2026, 9:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$RYAN
Neutral
medium confidence
Mentioned
$RYAN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RYANNeutralLow
01

Why it matters

The disclosure updates the record of insider activity and may influence short-term sentiment, but it does not provide new operating or financial guidance.

02

Market read

Traders may monitor insider activity for sentiment, but this specific sale is unlikely to be a standalone catalyst.

03

What to watch

The filing does not indicate whether the sale was part of a broader planned program, nor does it provide any change in business outlook or financial performance.

Relevance 3/10Novelty 3/10Timing: Filed 2026-08-14 after-hours; reflects sale executed 2026-08-13.

Background

This is an SEC Form 4 insider transaction for RYAN Specialty Holdings, reported by an executive (EVP and CHRO).

Company-level read

Ticker impact

$RYANNeutralMedium confidence
Context

RYAN Specialty Holdings disclosed an EVP and CHRO open-market sale of 2,043 shares at $42.2633 on 2026-08-13 via Form 4.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment.

Evidence & confidence

Form 4 insider sales are common and this one lacks additional context (no earnings, guidance, or operational change). The absence of a stated 10b5-1 plan can raise attention, but the disclosed size ($86.3K) is typically not material enough to drive fundamentals.

Market effects

No sector-level signal; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Insider sales can be driven by diversification or tax needs, so the market may overreact to the lack of a stated 10b5-1 plan.

Key entities

  • RYAN Specialty Holdings, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Conklin Michael

    EVP & CHRO who sold 2,043 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RYANMed

Ryan Specialty Holdings Inc (RYAN) (Q3 2026) Earnings Call Highlights: Revenue Growth

Ryan Specialty Holdings (RYAN) reported Q3 2026 revenue growth slowing to 4% from 15% YoY, with adjusted EBITDAC margin down 30 bps to 30.9%. The company cited market challenges, including property pricing declines and increased competition. Management expects continued pressure in Q4 2026 and 2027, with modest margin expansion anticipated. They also discussed growth opportunities in reinsurance and AI-related risks, and potential M&A activity in 2027.

Med

Ryan Specialty grows revenue as property softening squeezes E&S returns

Ryan Specialty reported a 4.7% revenue increase to $790M in Q3 2026, driven by casualty lines, while property revenue declined. Underwriting management grew 5.4%, expanding its share of total revenue. Expenses rose 9.9%, outpacing revenue growth. The company maintained its full-year guidance for mid-single-digit organic revenue growth and reported a 3.8% increase in adjusted EBITDAC to $244.4M.